# Safety and Efficacy Study of JNJ-64304500 in Participants With Moderately to Severely Active Crohn's Disease

> **NCT02877134** · PHASE2 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 388 (actual)

## Conditions studied

- Crohn Disease

## Interventions

- **DRUG:** JNJ-64304500
- **DRUG:** Placebo
- **DRUG:** Ustekinumab

## Key facts

- **NCT ID:** NCT02877134
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-08-25
- **Primary completion:** 2020-12-10
- **Final completion:** 2022-01-24
- **Target enrollment:** 388 (ACTUAL)
- **Last updated:** 2025-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02877134

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02877134, "Safety and Efficacy Study of JNJ-64304500 in Participants With Moderately to Severely Active Crohn's Disease". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02877134. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*